Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Cardiac Bio Solutions Launches MyCardia AT China Production with Shenzhen Ebulent

Fineline Cube Jan 16, 2026
Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Fineline Cube Jan 15, 2026
Company Deals

Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%

Fineline Cube Jan 15, 2026
Company Deals

Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T‑Cell Isolation in Cell Therapy

Fineline Cube Jan 15, 2026
Company Deals

WuXi Biologics Licenses Clinical‑Stage T‑Cell Engager to Zai Lab for Solid Tumor Development

Fineline Cube Jan 15, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Signet Therapeutics Completes Preclinical Study for SIGX2649, Pan‑TEAD Inhibitor for Solid Tumors

Fineline Cube Jan 16, 2026
Company Drug

Vitalgen’s VGN‑R08b Gene Therapy Earns FDA Orphan Drug Designation for Gaucher Disease

Fineline Cube Jan 16, 2026
Company Drug

Base Therapeutics’ NK510 Receives US FDA Clearance for Advanced Solid Tumor Studies

Fineline Cube Nov 25, 2024

Shanghai-based cell therapy specialist Base Therapeutics has achieved clearance from the US Food and Drug...

Company Deals

Merck KGaA Partners with NTU Singapore to Drive Digital Transformation with Trust Technology

Fineline Cube Nov 25, 2024

Merck KGaA (NYSE: MRK) has entered into a Memorandum of Understanding with the Digital Trust...

Company Drug

GSK’s Arexvy Receives MHLW Approval for Expanded RSV Indication in Japan

Fineline Cube Nov 25, 2024

UK-based pharmaceutical company GlaxoSmithKline (GSK; NYSE: GSK) has announced that Japan’s Ministry of Health, Labour...

Company Drug

China Resources Double-Crane Gets NMPA Approval for Semaglutide Biosimilar Clinical Trial

Fineline Cube Nov 25, 2024

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced that it has received clinical...

Company Drug

J&J Submits sBLA to FDA for Subcutaneous Tremfya Regimen in Ulcerative Colitis

Fineline Cube Nov 25, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to...

Company Drug

Servier’s Vorasidenib Approved in Boao Lecheng Medical Zone for Diffuse Gliomas

Fineline Cube Nov 25, 2024

French pharmaceutical company Servier’s Voranigo (vorasidenib), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor,...

Company Drug

Leads Biolabs’ LBL-024 Earns FDA Orphan Drug Designation for Neuroendocrine Cancer

Fineline Cube Nov 25, 2024

China-based Leads Biolabs Inc. has announced that it has obtained Orphan Drug Designation (ODD) from...

Company Drug

Signet Therapeutics’ SIGX1094 Earns Orphan Drug Designation for Gastric Cancer from FDA

Fineline Cube Nov 25, 2024

China-based Signet Therapeutics has announced that it has received Orphan Drug Designation (ODD) from the...

Company Deals

Hanx Biopharmaceuticals Files for IPO on Hong Kong Stock Exchange

Fineline Cube Nov 25, 2024

China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. has made an initial public offering (IPO) filing to...

Company Drug

MSD Partners with Cancer Foundation of China for HPV Vaccine Donation Program

Fineline Cube Nov 25, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a donation agreement with the...

Company Drug

Sciwind Biosciences’ Ecnoglutide Accepted for Review by China’s NMPA for Type 2 Diabetes

Fineline Cube Nov 25, 2024

China-based Sciwind Biosciences Co., Ltd has announced that the National Medical Products Administration (NMPA) has...

Company

Three Senior Executives of Henan Topfond Pharmaceutical Under Investigation

Fineline Cube Nov 24, 2024

On November 22, China General Technology (Group) Holding released three official announcements through its official...

Company

Leman Biotech Enters Zhongshan Life Science Park to Accelerate CAR-T Innovation

Fineline Cube Nov 24, 2024

Innovative biotechnology company Leman Biotech, focused on cutting-edge cell therapy technology, has announced its official...

Company

BRL Medicine Inc. Secures Nearly $30 Million in B+ Round Financing to Advance Pipeline

Fineline Cube Nov 23, 2024

On November 22, 2024, BRL Medicine Inc. announced the completion of nearly 200 million yuan...

Company

Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies

Fineline Cube Nov 23, 2024

On November 22, 2024, B&K Corporation Limited (Bio-Bank Corp.), a biopharmaceutical company headquartered in China,...

Company Drug

HutchMed Anticipates Milestone Payment as Takeda Launches Fruzaqla in Japan for CRC

Fineline Cube Nov 22, 2024

China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a milestone payment...

Company Drug

First Patient Dosed in Abbisko’s Phase II Trial of ABSK061 and ABSK043 in FGFR2/3 Altered Tumors

Fineline Cube Nov 22, 2024

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the first patient dosing in...

Company Drug

Bayer’s Nubeqa Files for FDA Approval in mHSPC

Fineline Cube Nov 22, 2024

German pharmaceutical company Bayer AG (ETR: BAYN) has announced that the US Food and Drug...

Company

MSD China to Streamline Diabetes Business Amid Volume-Based Procurement Inclusion

Fineline Cube Nov 22, 2024

The China unit of US pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK)...

Company Deals

Zai Lab Ltd Partners with Pfizer for Commercialization of Xacduro in China

Fineline Cube Nov 22, 2024

China-based biotechnology company Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced a strategic collaboration...

Posts pagination

1 … 205 206 207 … 610

Recent updates

  • Signet Therapeutics Completes Preclinical Study for SIGX2649, Pan‑TEAD Inhibitor for Solid Tumors
  • Vitalgen’s VGN‑R08b Gene Therapy Earns FDA Orphan Drug Designation for Gaucher Disease
  • Cardiac Bio Solutions Launches MyCardia AT China Production with Shenzhen Ebulent
  • Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal
  • Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Signet Therapeutics Completes Preclinical Study for SIGX2649, Pan‑TEAD Inhibitor for Solid Tumors

Company Drug

Vitalgen’s VGN‑R08b Gene Therapy Earns FDA Orphan Drug Designation for Gaucher Disease

Company Deals

Cardiac Bio Solutions Launches MyCardia AT China Production with Shenzhen Ebulent

Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.